Previous close | 28.00 |
Open | 0.00 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | 105,373 |
Market cap | 170.913B |
Beta (5Y monthly) | 0.57 |
PE ratio (TTM) | 7.50 |
EPS (TTM) | 3.76 |
Earnings date | 30 July 2024 |
Forward dividend & yield | 1.64 (5.31%) |
Ex-dividend date | 08 Nov 2023 |
1y target est | N/A |
Pfizer (PFE) closed at $27.99 in the latest trading session, marking a -1.3% move from the prior day.
Novavax (NVAX) seeks marketing authorization in the European Union for an updated version of its COVID-19 vaccine, which has been formulated to target the JN.1 variant.
The NHS has turned to US drugs giant Pfizer over its British rival GSK for vaccines against Respiratory Syncytial Virus (RSV), the winter infection known as the “silent killer” of the elderly.